Skin Boosters: A Clinical Guide for Practitioners

Bio-Revitalisation versus Volumisation: A Clinically Important Distinction

The term "skin booster" has become widely used in UK aesthetic practice, but it is not a regulatory or pharmacopoeial category. It is most usefully understood as a descriptor for injectables whose primary intended effect is bio-revitalisation: the improvement of skin hydration, texture, elasticity, and luminosity, rather than the addition of structural volume or the correction of a defined tissue deficit.

This distinction matters clinically for several reasons. First, it governs depth of injection; most skin boosters are placed intradermally or superficially subdermal, quite different from the deep supraperiosteal or subgaleal planes used for volumising fillers. Second, it shapes patient selection and expectation management; results from skin boosters are often described by patients as a global improvement in skin quality rather than a specific change in contour. Third, it informs the treatment interval design; skin boosters typically require a loading phase of two to three treatments followed by maintenance, whereas volumising fillers are often single-session procedures with touch-up at six to twelve months.

The term bio-revitalisation was given scientific currency by studies demonstrating that certain HA formulations, particularly those with a low degree of cross-linking or no cross-linking, stimulate fibroblasts to produce endogenous HA, collagen, and elastin rather than simply acting as mechanical volume replacers (published data from IBSA Farmaceutici and peer-reviewed work in the Journal of Drugs in Dermatology and Aesthetic Medicine).

Hyaluronic Acid-Based Skin Boosters

The majority of skin boosters used in UK practice are HA-based, but their rheological profiles are markedly different from those of structural dermal fillers. Low cross-linking density and low G-prime are deliberate design features that allow the product to integrate into the dermal matrix without creating a palpable bolus.

Profhilo (IBSA Farmaceutici)

Profhilo is one of the most clinically studied bio-remodelling injectables available in the UK. It is formulated using NAHYCO technology (Native Hybrid Cooperative Complexes), which produces a hybrid cooperative complex of high-molecular-weight (H-HA) and low-molecular-weight (L-HA) hyaluronic acid stabilised by thermal cross-linking rather than chemical BDDE cross-linking. The result is a highly fluid product with an exceptionally high HA concentration (64 mg per 2 ml) that spreads extensively through tissue from a small number of injection points.

NAHYCO technology's use of thermal stabilisation rather than chemical cross-linking means BDDE residuals are absent, which is a relevant consideration for patients with concerns about chemical sensitisation (IBSA SPC for Profhilo). The product is injected using the BAP (Bio Aesthetic Points) protocol, a standardised five-point per side technique for the face that was developed and validated by its originating practitioners to maximise distribution from a limited injection count.

Published clinical evidence for Profhilo includes randomised controlled data demonstrating improvements in skin laxity, elasticity, and dermal density at 28-day intervals following a two-session loading protocol (Casabona and Marchetti, Journal of Drugs in Dermatology, 2017; further peer-reviewed data in Aesthetic Surgery Journal). The product also has published evidence for use in off-face areas including the neck, decolletage, and hands.

Restylane Vital and Restylane Vital Light (Galderma)

Restylane Vital uses a low-cross-linked, biphasic HA gel (20 mg/ml) designed for intradermal injection to improve skin hydration and texture. Restylane Vital Light is a lower-concentration variant for finer skin and more superficial planes. Both products have a substantial evidence base, including randomised controlled trials and long-term follow-up data published across multiple peer-reviewed journals (Galderma SPC; Gubanova and Starovatova, Journal of Drugs in Dermatology, 2015).

Galderma's clinical data for the Vital range demonstrate statistically significant improvements in skin hydration, smoothness, and patient satisfaction compared to baseline, with effects maintained at six months following a three-session loading phase at monthly intervals.

Jalupro (IBSA Farmaceutici)

Jalupro is a hybrid product combining HA with a proprietary amino acid complex (glycine, L-proline, L-leucine, and L-lysine) designed to stimulate fibroblast collagen synthesis. It is available in Classic and HMW (high-molecular-weight) formulations. The amino acid component distinguishes Jalupro from pure HA skin boosters and positions it closer to the mesotherapy spectrum, though it is frequently grouped with bio-revitalisers in clinical practice. Manufacturer data and independent case series support its use for skin quality improvement, particularly in photodamaged and prematurely aged skin (IBSA SPC for Jalupro).

Juvederm Volite (Allergan Aesthetics)

Juvederm Volite uses Vycross cross-linking technology but at a lower cross-link density than the structural Juvederm range, producing a highly fluid gel intended for intradermal injection. It is licensed for use in the face, neck, decolletage, and hands. A 12-month randomised controlled trial (Rzany et al., Journal of the European Academy of Dermatology and Venereology, 2017) demonstrated sustained improvements in skin smoothness and hydration at 9 months post-treatment following a single session, which distinguishes its durability profile from some competitor products that require two or three loading sessions.

Non-HA Skin Boosters

Sunekos (Professional Dietetics)

Sunekos is a patented formulation of HA combined with a specific ratio of six amino acids (glycine, L-proline, L-leucine, L-lysine, L-valine, and L-alanine) designed to stimulate the synthesis of elastin in addition to collagen, by providing the substrate precursors for extracellular matrix regeneration. It is available as Sunekos 200 (lower molecular weight, for superficial skin rejuvenation) and Sunekos 1200 (higher molecular weight, for deeper tissue bio-revitalisation).

The patented formulation is based on the Fibroblast Activation Technology (FAT) platform, which describes the mechanism of fibroblast stimulation by specific amino acid ratios. Peer-reviewed clinical data, including a study published in the Journal of Cosmetic Dermatology (Del Fattore et al., 2020), support improvements in skin elasticity, density, and wrinkle depth over a standard four-session protocol. Sunekos does not produce volumisation and is not appropriate as a filler substitute.

Patient Selection

Skin boosters are appropriate for a broad range of patients seeking general skin quality improvement rather than structural change. Patient selection criteria for the category as a whole include the following considerations.

Skin laxity and reduced hydration in the absence of significant volume loss, where bio-revitalisation rather than volumisation is the clinical priority.
Photodamaged or prematurely aged skin, where improvements in texture and radiance are the desired outcome.
Younger patients seeking preventive or maintenance treatment, where the goal is support of intrinsic collagen and HA production rather than correction of established volume deficit.
Patients who are not ready or appropriate for structural filler procedures, but who would benefit from an evidence-based injectable approach to skin quality.
Post-isotretinoin patients, where skin quality improvement is a goal but inflammatory risk must be assessed (relative contraindication; seek dermatological advice where isotretinoin has been taken within 6 months).

Skin boosters are frequently used in combination with dermal fillers; for example, structural volumisation with a high G-prime filler at the mid-face followed by a course of bio-remodelling treatment to improve overall skin quality. This combination approach is well-supported by clinical practice guidelines from BCAM and is described in published treatment algorithms (see Aesthetic Medicine journal).

View the complete skin booster range available from Longeva Aesthetics at /collections/skin-boosters.

Treatment Intervals and Protocol Design

Most HA skin boosters follow a loading-plus-maintenance structure. A typical protocol for Profhilo, for example, consists of two sessions spaced four weeks apart, followed by a maintenance session at six months. The Restylane Vital programme commonly employs three sessions at monthly intervals, with maintenance at six to nine months depending on the patient's response. Jalupro and Sunekos protocols typically specify four sessions at weekly or fortnightly intervals for the loading phase.

Patient response varies considerably and is influenced by age, lifestyle factors (UV exposure, smoking, nutritional status), skin type, and degree of existing photodamage. Practitioners should set realistic expectations at consultation and base their maintenance interval recommendations on observed clinical response rather than manufacturer protocol alone.

Contraindications

Contraindications broadly mirror those for HA dermal fillers, with the following additions relevant to this product class.

Known hypersensitivity to any constituent of the formulation, including HA and any amino acid component in combination products.
Active infection, inflammation, or skin condition at the proposed injection site.
Pregnancy and breastfeeding (contraindicated per manufacturer SPC for all products in this category; insufficient safety data).
Autoimmune skin conditions such as active lupus or scleroderma at the proposed treatment site (relative contraindication; seek specialist input).
Coagulopathies or current anticoagulant therapy.
Recent ablative resurfacing, chemical peel, or laser treatment in the planned treatment zone (allow appropriate healing interval; typically four to six weeks minimum; consult current BCAM guidance).

Regulatory Status

HA-based skin boosters are classified as Class III medical devices under the UK Medical Devices Regulations 2002, consistent with the MHRA's classification of all injectable HA products. The same verification obligations apply to skin boosters as to dermal fillers: UK CA mark, MHRA Device Registration record, and verified cold-chain supply from the distributor. Practitioners in England also require a CQC licence for injectable procedures, as noted under the Health and Care Act 2022.

Non-HA products such as Sunekos are also regulated as Class III medical devices in the UK. Practitioners should confirm regulatory status with the supplier before clinical use and retain documentation in their clinical governance records.

See all bio-revitalisation and skin quality injectables available from Longeva Aesthetics at /collections/all-products. You may also find it useful to compare skin booster options alongside the broader dermal filler range when planning a combination treatment protocol.

Evidence Quality and Limitations

The evidence base for skin boosters is more heterogeneous than that for structural fillers. Some products, notably Profhilo and Restylane Vital, have randomised controlled trial data published in peer-reviewed journals. Others, including several newer entrants to the market, have primarily case series or manufacturer-sponsored data. Practitioners are encouraged to appraise evidence quality using standard clinical tools (GRADE or SIGN methodology) rather than accepting manufacturer marketing as a substitute for independent research.

The Journal of Cosmetic Dermatology, Aesthetic Surgery Journal, and Aesthetic Medicine are the most relevant peer-reviewed sources for practitioners seeking independent literature on this product category. The BCAM position papers on bio-revitalisation (available via bcam.co.uk) provide a practical synthesis of the available evidence alongside clinical practice recommendations.

Frequently Asked Questions

What is the difference between a skin booster and a dermal filler?

Skin boosters are designed for bio-revitalisation: improving skin hydration, elasticity, and texture by stimulating the skin's own matrix-producing cells. They are injected at a superficial intradermal depth and spread through tissue rather than creating a defined volume. Dermal fillers, by contrast, are placed more deeply to correct a structural volume deficit or redefine a contour, and they have a higher G-prime (stiffness) that allows them to resist deformation and provide mechanical support. The two categories are complementary and are often used together in a comprehensive facial treatment plan.

How many sessions of Profhilo are typically needed?

The standard IBSA-recommended protocol for Profhilo consists of two sessions spaced four weeks apart as a loading phase, followed by a single maintenance session at approximately six months. Clinical trial data (Casabona and Marchetti, Journal of Drugs in Dermatology, 2017) demonstrated measurable improvements in skin laxity and elasticity at 28-day intervals. Individual patient response varies, and some practitioners adjust the maintenance interval based on observed skin quality at follow-up. Practitioners should consult the current Profhilo SPC and IBSA clinical training materials for the most up-to-date protocol guidance.

Can skin boosters be used safely in combination with dermal fillers?

Yes. Combination use of structural fillers and skin boosters is common and well-supported by clinical practice guidelines from the British College of Aesthetic Medicine (BCAM). A typical combination approach might involve volumisation at the mid-face with a high G-prime structural filler followed by a course of bio-remodelling treatment to improve overall skin quality and hydration. The sequencing and interval between procedures depends on the products used; practitioners should review the relevant SPCs and consult BCAM guidance on combination protocols. Patients should be assessed individually for suitability for combined treatment.

What is NAHYCO technology in Profhilo?

NAHYCO stands for Native Hybrid Cooperative Complexes. It is a proprietary manufacturing process developed by IBSA Farmaceutici that thermally stabilises a hybrid complex of high-molecular-weight and low-molecular-weight HA without the use of chemical cross-linking agents such as BDDE. The resulting product has a very high HA concentration (64 mg per 2 ml) and a highly fluid rheology that allows it to spread extensively through tissue from a small number of injection points. The absence of BDDE residuals is a relevant consideration for certain patient populations. Full technical specifications are available in the Profhilo SPC and IBSA product data.

Are skin boosters regulated as medical devices in the UK?

Yes. All injectable HA products, including skin boosters, are classified as Class III medical devices under the UK Medical Devices Regulations 2002 following MHRA reclassification. Class III requires conformity assessment by a UK Approved Body and registration on the MHRA's device register. Practitioners must verify that any product they purchase and use carries the appropriate regulatory authorisation; suppliers should be able to provide device registration documentation on request. Longeva Aesthetics holds regulatory documentation for all products supplied through the platform.